H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer's disease, Bipolar disorder, depression, epilepsy, Huntington's disease, Parkinson's disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer's disease, Azilect for the treatment of Parkinson's disease, Xenazine for the treatment of Huntington's disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTC:HLUYY
- CUSIP: N/A
- Web: www.lundbeck.com
- Market Cap: $11.92 billion
- Outstanding Shares: 197,300,000
- 50 Day Moving Avg: $55.70
- 200 Day Moving Avg: $48.12
- 52 Week Range: $31.00 - $60.78
Sales & Book Value:
- Trailing P/E Ratio: 48.19
- P/E Growth: 0.00
- Annual Revenue: $2.47 billion
- Price / Sales: 4.83
- Book Value: $7.64 per share
- Price / Book: 7.91
- EBIDTA: $629.13 million
- Net Margins: 9.96%
- Return on Equity: 27.04%
- Return on Assets: 12.49%
- Debt-to-Equity Ratio: 0.17%
- Current Ratio: 1.07%
- Quick Ratio: 0.81%
- Average Volume: 7,041 shs.
- Beta: 0.32
Frequently Asked Questions for H Lundbeck A/S (OTC:HLUYY)
What is H Lundbeck A/S's stock symbol?
H Lundbeck A/S trades on the OTC under the ticker symbol "HLUYY."
Who are some of H Lundbeck A/S's key competitors?
Some companies that are related to H Lundbeck A/S include C.R. Bard (BCR), Cerner Corporation (CERN), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Quintiles Transitional Holdings (Q), Laboratory Corporation of America Holdings (LH), BioMarin Pharmaceutical (BMRN), Eisai Co., Ltd (ESALY), Smith & Nephew SNATS (SNN), Quest Diagnostics Incorporated (DGX), IDEXX Laboratories (IDXX), Henry Schein (HSIC), Centene Corporation (CNC), DENTSPLY SIRONA (XRAY), Grifols, S.A. (GRFS), Genmab A/S (GNMSF), Olympus Corp. (OCPNY) and DaVita HealthCare Partners (DVA).
Who are H Lundbeck A/S's key executives?
H Lundbeck A/S's management team includes the folowing people:
- Lars Rasmussen, Independent Chairman of the Board
- Kaare Schultz, President, Chief Executive Officer
- Lene Skole, Deputy Chairman of the Board
- Anders Goetzsche, Chief Financial Officer, Executive Vice President
- Staffan Schueberg, Executive Vice President, Chief Commercial Officer
- Lars Bang, Executive Vice President, Supply Operations & Engineering
- Anders Gersel Pedersen M.D., Ph.D., Executive Vice President, Research and Development
- Jacob Tolstrup, Executive Vice President, Corporate Functions
- Mona Elisabeth Elster, Director, Employee Representative
- Lars Holmqvist, Director
How do I buy H Lundbeck A/S stock?
Shares of H Lundbeck A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is H Lundbeck A/S's stock price today?
MarketBeat Community Rating for H Lundbeck A/S (OTC HLUYY)MarketBeat's community ratings are surveys of what our community members think about H Lundbeck A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of H Lundbeck A/S stock can currently be purchased for approximately $60.43.
Consensus Ratings for H Lundbeck A/S (OTC:HLUYY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for H Lundbeck A/S (OTC:HLUYY)
(Data available from 7/23/2015 forward)
|4/12/2017||Jefferies Group LLC||Downgrade||Buy -> Hold|
Earnings History for H Lundbeck A/S (OTC:HLUYY)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for H Lundbeck A/S (OTC:HLUYY)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for H Lundbeck A/S (OTC:HLUYY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for H Lundbeck A/S (OTC:HLUYY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for H Lundbeck A/S (OTC:HLUYY)
Latest Headlines for H Lundbeck A/S (OTC:HLUYY)